Pirfenidone Capsule
Product Images NDC 42291-490

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Pirfenidone (NDC 42291-490). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Avkare, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (490 27)

Pirfenidone Capsules 267 mg oral dosage form packaging label by AvKARE. The label includes the proprietary and generic name, strength of 267 mg per capsule, and package size of 270 capsules. It features storage instructions to keep at 20° to 25°C, directions to keep out of reach of children, and manufacturer details including AvKARE and Amneal Pharmaceuticals.*

FDA Label Image

10 (Pirfenidone Capsules Us Mfd 1)

Chemical structure of pirfenidone showing a pyridone ring substituted with a methyl group and a phenyl group attached to the nitrogen atom of the ring.*

FDA Label Image

10 (Pirfenidone Capsules Us Mfd 2)

A line chart showing the cumulative percentage of patients versus the absolute change in %FVC (forced vital capacity) from baseline to week 52 for Pirfenidone and placebo groups. The x-axis represents absolute change in %FVC ranging from -30 to 10%, with worsening (decrease) on the left and no decline (increase) on the right. The y-axis shows the percentage of patients from 0 to 100%. The Pirfenidone group is represented by a solid line, and the placebo group by a dotted line. Percentages at certain points indicate, for example, 32% placebo patients versus 17% Pirfenidone patients showing declines around -10%, and 90% placebo versus 77% Pirfenidone patients showing no decline or improvement in %FVC.*

FDA Label Image

10 (Pirfenidone Capsules Us Mfd 3)

A line graph showing mean change in FVC (mL) over 52 weeks comparing Pirfenidone (n=278) to placebo (n=277). The X-axis represents time in weeks, and the Y-axis represents mean change in FVC. Pirfenidone shows less decline in FVC compared to placebo across the study period.*

FDA Label Image

10 (Pirfenidone Capsules Us Mfd 4)

A Kaplan-Meier survival curve chart showing the percentage of patients alive over time in weeks for Pirfenidone versus placebo groups. The chart compares survival rates between 0 and 120 weeks, with the number of patients at risk listed below the x-axis, and includes a hazard ratio with confidence interval.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.